May 16, 2022 - Health

"Fashionably late" Novavax is confident approval is coming

Tina Reed

Illustration of a syringe drawing vaccine out of a vial. — Illustration: Brendan Lynch/Axios

Officials at Novavax say they're confident their COVID-19 vaccine will receive an emergency use authorization from the FDA early next month, CNBC reports.

Why it matters: The Maryland company received $1.6 billion from the federal government to speed the development of the shots early during the pandemic but has yet to make it to the U.S. market.

Yet its protein-based COVID vaccine — which uses moth cells to produce shots — has been slowly gaining favor in the EU and the U.K.
The biotech's request for authorization is scheduled for a review on June 7 by a key FDA advisory committee.

Be smart: While Novavax is "fashionably late to the COVID-19 vaccine party," as FiercePharma put it last month, it could be well-positioned as the pandemic drags 0n and questions about the durability of other vaccines remain.

Add Axios on Google

"Fashionably late" Novavax is confident approval is coming

What to read next